DOCSLIB.ORG

Federal Register/Vol. 76, No. 22/Wednesday, February 2, 2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 76, No. 22/Wednesday, February 2, 2011 Federal Register / Vol. 76, No. 22 / Wednesday, February 2, 2011 / Notices 5829 Dated: January 18, 2011. Dated: January 18, 2011. Joseph T. Rannazzisi, Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Deputy Assistant Administrator, Office of Sched- Drug ule Diversion Control, Drug Enforcement Diversion Control, Drug Enforcement Administration. Administration. Meperidine (9230) .......................... II [FR Doc. 2011–2284 Filed 2–1–11; 8:45 am] [FR Doc. 2011–2288 Filed 2–1–11; 8:45 am] Metazocine (9240) ......................... II BILLING CODE 4410–09–P BILLING CODE 4410–09–P Methadone (9250) .......................... II Morphine (9300) ............................. II Thebaine (9333) ............................. II DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Levo-alphacetylmethadol (9648) .... II Remifentanil (9739) ........................ II Drug Enforcement Administration Drug Enforcement Administration Carfentanil (9743) .......................... II Fentanyl (9801) .............................. II Manufacturer of Controlled Manufacturer of Controlled Substances; Notice of Application Substances; Notice of Application The company plans to manufacture Pursuant to § 1301.33(a), Title 21 of reference standards. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), Any other such applicant, and any the Code of Federal Regulations (CFR), this is notice that on November 24, person who is presently registered with DEA to manufacture such substances, this is notice that on May 25, 2010, 2010, Sigma Aldrich Research may file comments or objections to the AMRI Rensselaer, Inc., 33 Riverside Biochemicals, Inc., 1–3 Strathmore issuance of the proposed registration Avenue, Rensselaer, New York 12144, Road, Natick, Massachusetts 01760– 2447, made application by renewal to pursuant to 21 CFR 1301.33(a). made application by renewal to the Any such written comments or Drug Enforcement Administration the Drug Enforcement Administration (DEA) to be registered as a bulk objections should be addressed, in (DEA) to be registered as a bulk quintuplicate, to the Drug Enforcement manufacturer of the following basic manufacturer of the following classes of controlled substances: Administration, Office of Diversion classes of controlled substances: Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Drug Schedule Springfield, Virginia 22152; and must be filed no later than April 4, 2011. Marihuana (7360) ......................... I Sched- Drug ule Tetrahydrocannabinols (7370) ..... I Dated: January 18, 2011. Amphetamine (1100) .................... II Cathinone (1235) ........................... I Joseph T. Rannazzisi, Lisdexamfetamine (1205) ............. II Methcathinone (1237) .................... I Deputy Assistant Administrator, Office of Methylphenidate (1724) ................ II Aminorex (1585) ............................. I Diversion Control, Drug Enforcement Pentobarbital (2270) ..................... II Alpha-ethyltryptamine (7249) ......... I Administration. Meperidine (9230) ........................ II Lysergic acid diethylamide (7315) I [FR Doc. 2011–2237 Filed 2–1–11; 8:45 am] Fentanyl (9801) ............................ II Tetrahydrocannabinols (7370) ....... I BILLING CODE 4410–09–P 4-Bromo-2,5- I dimethoxyamphetamine (7391). The company plans to manufacture 4-Bromo-2,5- I DEPARTMENT OF JUSTICE bulk controlled substances for use in dimethoxyphenethylamine (7392). 2,5-Dimethoxyamphetamine (7396) I product development and for Drug Enforcement Administration distribution to its customers. 3,4-Methylenedioxyamphetamine I (7400). In reference to drug code 7360 N-Hydroxy-3,4- I Manufacturer of Controlled (Marihuana), the company plans to bulk methylenedioxyamphetamine Substances; Notice of Registration manufacture cannabidiol as a synthetic (7402). By Notice dated August 3, 2010, and 3,4-Methylenedioxy-N- I intermediate. This controlled substance published in the Federal Register on will be further synthesized to bulk ethylamphetamine (7404). 3,4- I September 1, 2010, 75 FR 53719, manufacture a synthetic THC (7370). No Methylenedioxymethamphetami- Cambridge Isotope Lab, 50 Frontage other activity for this drug code is ne (MDMA) (7405). Road, Andover, Massachusetts 01810, authorized for this registration. Psilocybin (7437) ............................ I made application by renewal to the Any other such applicant, and any 5-Methoxy-N,N- I Drug Enforcement Administration diisopropyltryptamine (7439). person who is presently registered with (DEA) to be registered as a bulk 1-[1-(2- I manufacturer of Morphine (9300), a DEA to manufacture such substances, Thienyl)cyclohexyl]piperidine may file comments or objections to the (TCP) (7470). basic class of controlled substance listed issuance of the proposed registration N-Benzylpiperazine (BZP) (7493) .. I in schedule II. pursuant to 21 CFR 1301.33(a). Heroin (9200) ................................. I The company plans to utilize small Normorphine (9313) ....................... I quantities of the listed controlled Any such written comments or Amphetamine (1100) ...................... II substance in the preparation of objections should be addressed, in Methamphetamine (1105) .............. II analytical standards. quintuplicate, to the Drug Enforcement Nabilone (7379) .............................. II No comments or objections have been Administration, Office of Diversion 1-Phenylcyclohexylamine (7460) ... II received. DEA has considered the Control, Federal Register Representative Phencyclidine (7471) ...................... II factors in 21 U.S.C. 823(a) and Cocaine (9041) ............................... II (ODL), 8701 Morrissette Drive, Codeine (9050) .............................. II determined that the registration of Springfield, Virginia 22152; and must be Diprenorphine (9058) ..................... II Cambridge Isotope Lab to manufacture filed no later than April 4, 2011. Ecgonine (9180) ............................. II the listed basic class of controlled Levomethorphan (9210) ................. II substance is consistent with the public Levorphanol (9220) ........................ II interest at this time. DEA has VerDate Mar<15>2010 16:00 Feb 01, 2011 Jkt 223001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 E:\FR\FM\02FEN1.SGM 02FEN1 srobinson on DSKHWCL6B1PROD with NOTICES.
Load more

Recommended publications
  • Analysis of Benzylpiperazine-Like Compounds Hiroyuki Inoue 1
    鑑識科学，9(2)，165―184(2004) 165 ―Technical Note― Analysis of Benzylpiperazine-like Compounds Hiroyuki Inoue1,YukoT.Iwata1, Tatsuyuki Kanamori1, Hajime Miyaguchi1, Kenji Tsujikawa1, Kenji Kuwayama1, Hiroe Tsutsumi2, Munehiro Katagi2, Hitoshi Tsuchihashi2 and Tohru Kishi1 National Research Institute of Police Science 631, Kashiwanoha, Kashiwa, Chiba 2770882, Japan1 Forensic Science Laboratory, Osaka Prefectural Police H. Q. 1318, Hommachi, Chuo-ku, Osaka, Osaka 5410053, Japan2 (Received 6 January 2004; accepted 6 March 2004) 1-Benzylpiperazine (BZP) and 1-(3-tri‰uoromethylphenyl)piperazine, newly controlled as narcotics in Japan on 2003, and their analogues were analyzed. The analytical data with color test, thin layer chromatography (TLC), infrared spectroscopy (IR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) are presented. The BZP-like compounds were less sensitive to Simon's reagent than amphetamine type stimulants on spot plates. Using on-site screening kit based on Simon's test (X-Checker), BZP indicated almost the same result as methamphetamine. For TLC, the solvent system, methanol －25 aqueous ammonia (100 : 1.5), was the best among the systems examined. Iodoplatinate reagent was the most sensitive one to detect BZP. The IR spectra showed su‹cient diŠerences to make identiˆcation. Trimethylsilylation was the most appropriate choice for the GC/MS analysis of BZP-like compounds in terms of the peak shapes, separation and stability (using a J&W DB-5MS column). In LC/MS analysis, the gradient elution (10 mM formic acid and acetonitrile) using a Waters Symmetry Shield C18 column achieved discrimination of isomers except for 1-(2-‰uorophenyl) piperazine and 1-(4-‰uorophenyl)piperazine.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • I PA Department of Health (2) I.D. Number (Governor's Office Use) (3) Short Title Amending the Schedules of Controlled Substance
    I PA Department of Health (2) I.D. Number (Governor's Office Use) (3) Short Title Amending the schedules of controlled substances. (4) PA Code Cite (5) Agency Contacts & Telephone Numbers 1 28 PA Code 8 25.72 Primary Contact: Carol Williams (717) 783-8665 Secondary Contact: Janice Staloski (717) 783-1379 I I (6) Type of Rulemaking (check one) I (7) Is a 120-Day Emergency Certification Attached' Proposed Rulemaking J No .\I Final Order Adopting Regulation Yes: By the Attorney General Final Order, Proposed Rulemaking Omitted Yes: By the Governor I (8) Briefly explain the regulation in clear and non technical language. The Department adopts amendments the schedule of controlled substances at 28 Pa. Code § 25.72. These regulations contain five schedules of controlled substances which categorize substances according to different potentials for abuse and medical use. A controlled substance is placed in Schedule I when there is a high potential for abuse; no currently accepted medical use in the United States; and a lack of accepted safety for use under medical supervision. The final rulemaking schedules five substances in Schedule I. 1 - (3 - trifluoromethylphenyl) Piperazine (TFMPP), N-Benzylpiperazine (BZP), Alpha-Methyltryptamine (AMT), 2,5 Dimethoxy - 4- (N) - Propylthiophenethylamine, and 5 - Methoxy - N, N - Diisopropyltryptamine (5-MEO-DIPT) will be scheduled as Schedule I controlled substances. Page 1 of 7 The final rulemaking to the Schedule I of controlled substances follow similar actions by the Federal Drug Enforcement Agency PEA). (9) State the statutory authority for the regulation and any relevant state or federal court decisions. The amendments to the schedules of controlled substances are promulgated pursuant to Sections 3 and 4 of the act (35 P.S.
    [Show full text]
  • Alltech® Drug Standards for the Forensic, Clinical & Pharmaceutical Industries OH
    Alltech® Drug Standards For the Forensic, Clinical & Pharmaceutical Industries OH H3C H H H3C H HO Catalog #505B Our Company Welcome to the Grace's Alltech® Drug Standards Catalog W. R. Grace has manufactured high-quality silica for over 150 years. Grace has been behind the scenes for the past 30 years supplying silica to the chromatography industry. Now we’re in the forefront moving beyond silica, developing and delivering innovative complementary products direct to the customer. Grace Davison Discovery Sciences was founded on Grace’s core strength as a premier manufacturer of differentiated media for SPE, Flash, HPLC, and Process chromatography. This core competency is further enhanced by bringing seven well-known global separations companies together, creating a powerful new single source for all your chromatography needs. A Full Portfolio of Chromatography Products to Support Drug Standards: • HPLC Columns • HPLC Accessories • Flash Products • TLC Products • GC Columns • GC Accessories • SPE and Filtration • Equipment • Syringes • Tubing • Vials For complete details, download the Chromatography Essentials catalog from the Grace web site or contact your customer service representative. Alltech - Part of the Grace Family of Products In 2004, Alltech Associates Inc. was acquired by Grace along with the Alltech® Drug Standards product line. Through investment in research and strategic acquisitions, Grace has expanded our product range and global reach while drawing upon the support of the Grace corporate infrastructure and more than 6000 employees globally to support scientific research and analysis worldwide. With key manufacturing sites in North and South America, Europe, and Asia, plus an extensive international sales and distribution network, separation scientists throughout the world can count on timely delivery and expert local technical service.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Rapid Screening for and Simultaneous Semiquantitative Analysis of Thirty Abused Drugs in Human Urine Samples Using Gas Chromatography-Mass Spectrometry" by T
    Journal of Analytical Toxicology, Vol. 30, September 2006 Rapid Screeningfor and SimultaneousSemiquantitative Analysisof Thirty Abused Drugs in Human Urine Samples Using Gas Chromatography- Mass Spectrometry Downloaded from https://academic.oup.com/jat/article/30/7/468/711520 by guest on 01 October 2021 Tomomi Ishida 1, Keiko Kudo 1, Hiromasa Inoue 1, Akiko Tsuji1, Takashi Kojima 2, and Noriaki Ikeda 1,* 1Department of Forensic Pathology and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan and 2Kanagawa Prefectural Institute of Public Health, Kanagawa 253-0087, Japan Abstract[ signer drugs, piperazine, tryptamine, and phenethylamine derivatives, are being widely abused among juveniles (1). Also, illicit use of opiates and the anesthetic drug ketamine (KET), In Japan, a wide variety of designer drugs became popular among which is known as or "Special is spreading (2,3). These juveniles because of their availability via the Internet and mobile "K" K', phones. Hence, it is necessary to develop simple and rapid designer drugs are sold as tablets or powder and are easily screening method for these drugs. We devised a rapid screening purchased via the Internet and mobile phones. method for and simultaneous semiquantitative analysis of 30 It is said that the classical stimulants, amphetamine (AP) abused drugs, including amphetamines, amphetamine-, and MA, mainly enhance dopamine-mediated neurotransmis- piperazine-, tryptamine-, and pbenethylamine-derived designer sion, leading to potent stimulant effects (4,5), whereas newer drugs and opiates in human urine. The urine sample was digested designer drugs such as amphetamine, piperazine, tryptamine, with urease, and the drugs were analyzed by gas chromatography- and phenethylamine derivatives mainly enhance serotonin- mass spectrometry in the scan mode after solid-phase extraction mediated neurotransmission, leading to psychedelic experi- with a FocusTM column and acetylation.
    [Show full text]
  • Regulation of the Department of Consumer Protection Concerning
    Secretary of the State File Number 6135 Regulation of the Department of Consumer Protection Concerning Controlled Substances Regulations adopted after July 1, 2013, become effective upon posting to the website of the Secretary of the State, or at a later date specified within the regulation. Website posted on September 17, 2013 Effective Date September 17, 2013 Approved by the Attorney General on December 28, 2012 Approved by the Legislative Regulation Review Committee on August 27, 2013 Received and filed in the Office of the Secretary of the State on September 10, 2013 Electronic copy with agency head certification statement submitted to the Office of the Secretary of the State on September 12, 2013 Published in the Connecticut Law Journal on STATE OF CONNECTICUT REGULATION of the DEPARTMENT OF CONSUMER PROTECTION concerning CONTROLLED SUBSTANCES Section 1. Subsection (c) of Section 21a-243-7 of the Regulations of Connecticut State Agencies is amended to read as follows: (c) Any material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine; (2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA; (3) 2,5-dimethoxyamphetamine; or 2,5-DMA; (4) 2,5-Dimethoxy-4-ethylamphetamone or DOET; (5) 3,4-M ethylenedioxy-N-ethylamphetamine; (6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP; (7) 3,4-methylenedioxymethamphetamine;
    [Show full text]
  • New Psychoactive Substances and Stimulants
    New Psychoactive Substances and Stimulants Gilberto Gerra Chief Drug Prevention and Health Branch Million % Heroin Prescription opioid 53.3 1.08 53.3 Cocaine 18.0 0.37 Amphetamines 28.9 0.59 68.2 Ecstasy 21.3 0.41 Past year, World Drug Report 2019 Stimulants among NPS Methyl-meth-cathinone (Mephedrone) Phenethylamines Benzylpiperazine Synthetic cannabinoids Services for people affected by stimulants use disorders and NPS use: - Not available - Unprepared - Empty - Not appealing - Laboratory inability - Counselling - Psychosocial interventions only NPS: "Internet drugs/designer drugs/legal highs" in Sweden Among 189 cases of drug intoxications at emergency departments and intensive care units 50 substances identified: - synthetic cannabinoid receptor agonists ("Spice") - piperazines - substituted phenethylamines - synthetic cathinones - hallucinogenic tryptamines Helander et al., 2014 New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? 173 samples believed to be MDMA, amphetamine, cocaine, mescaline, or methamphetamine. The NPS adulterant most frequently observed 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine (2C-B) - 69 different combinations of substances were detected: - 20 involving a controlled drug combined with an NPS - 49 involving one or more NPS that substituted the controlled drug Giné et al., 2014 Int J Drug Policy. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users. Sande, 2016 Int J Drug Policy. I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances. Matthews et al., 2017 Users attributed greater risks to the use of new drugs and preferred the effects of traditional drugs: - depression (55.2% of users), - concentration difficulties (44.0%), - feelings of fear and anxiety (39.4%), - tingling in the arms or legs (34.4%).
    [Show full text]